CG
BMRN icon

Clinton Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Clinton Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,527
Closed -$514K – 393
2017
Q3 		$514K Sell
5,527
-6,272
-53% -$554K 0.06% 287
2017
Q2 		$1.07M Buy
+11,799
New +$1.07M 0.11% 272
2015
Q4 		– Sell
-3,126
Closed -$329K – 758
2015
Q3 		$329K Buy
+3,126
New +$418K 0.03% 532
2015
Q2 		– Sell
-1,891
Closed -$236K – 584
2015
Q1 		$236K Buy
+1,891
New +$200K 0.06% 404

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clinton Group's BMRN Position: Q4 2017 in Review

Clinton Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 5,527 shares — an estimated $514K sold.

Clinton Group first reported a position in BMRN in Q1 2015 and held it in 4 quarters. The position peaked at $1.07M in Q2 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Clinton Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Clinton Group sold 5,527 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $514K.
  • Clinton Group first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Clinton Group's BioMarin Pharmaceuticals position peaked at $1.07M in Q2 2017.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Clinton Group's 13F filing for Q4 2017, filed 14 Feb 2018.